Abstract: Objective: To evaluate the effects of celecoxib combined with oxaliplatin on tumor growth, survivin expression and angiogenesis in lung cancer xenografts in nude mice. Methods: Human lung cancer A549 cells were injected into BALB/c nude mice subcutaneously. The mice were randomly divided into 4 groups: the control group, the Oxaliplatin group, the Celecoxib group and the Celecoxib combined with Oxaliplatin group. On the 42nd day after treatment, tumor tissues were collected and assessed for the detection of COX-2, VEGF, Survivin, and microvessel density (MVD) by immunohistochemistry and RT-PCR. Results: The rate of tumor inhibition was 34.60% in the Celecoxib group, 46.70% in the Oxaliplatin group and 66.09% in the Celecoxib combined with Oxaliplatin group. Immunohistochemical and RT-PCR analysis showed an increase in the expression of COX-2 and VEGF, a decrease in the expression of Survivin in the Oxaliplatin group (compared with the control group, P<0.05), and no obvious differences in MVD (compared with the control group, P>0.05). The expression of COX-2, VEGF, Survivin and MVD was significantly decreased in the Celecoxib group and the Celecoxib combined with Oxaliplatin group. Conclusion: Celecoxib can suppress tumor growth, angiogenesis and expression of Survivin and it can enhance the anti-tumor effect of Oxaliplatin.